Page last updated: 2024-11-07

2'-deoxycytidine diphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID150855
CHEBI ID28846
SCHEMBL ID158324
MeSH IDM0133041

Synonyms (32)

Synonym
deoxycytidine diphosphate
d-1beta-ribofuranosylcytosine diphosphate
2'-deoxycytidine 5'-(trihydrogen diphosphate)
CHEBI:28846
cytidine, 2'-deoxy-, 5'-(trihydrogen pyrophosphate)
2(1h)-pyrimidinone, 4-amino-1-[2-deoxy-5-o-[hydroxy(phosphonooxy)phosphinyl]-beta-d-erythro-pentofuranosyl]-
cytidine 5'-(trihydrogen diphosphate), 2'-deoxy-
cytidine, 2'-deoxy-, 5'-pyrophosphate
deoxy-cdp
1beta-ribofuranosylcytosine diphosphate, d-
cytidine, 2'-deoxy-, pyrophosphate
deoxycytidine 5'-diphosphate
800-73-7
DCDP ,
2'-deoxycytidine-5'-diphosphate
2'-deoxycytidine diphosphate
2'-deoxycytidine 5'-diphosphate
C00705
yyy ,
unii-m07s1bkn37
m07s1bkn37 ,
SCHEMBL158324
[({[(2r,3s,5r)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]phosphonic acid
FTDHDKPUHBLBTL-SHYZEUOFSA-N
4-amino-1-[2-deoxy-5-o-[hydroxy(phosphonooxy)phosphinyl]-beta-d-erythro-pentofuranosyl]-2(1h)-pyrimidinone
4-amino-1-[2-deoxy-5-o-[hydroxy(phosphonooxy)phosphinyl]-beta-delta-erythro-pentofuranosyl]-2(1h)-pyrimidinone
delta-1beta-ribofuranosylcytosine diphosphate
2'-deoxy-cytidine pyrophosphate
2'-deoxy-cytidine 5'-pyrophosphate
Q55168710
((2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl trihydrogen diphosphate
DTXSID301027111
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2'-deoxycytidine phosphate
pyrimidine 2'-deoxyribonucleoside 5'-diphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Pyrimidine Metabolism2353
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Pyrimidine Deoxyribonucleosides Salvage815
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
ATP + dCDP = ADP + dCTP ( Pyrimidine Nucleotides and Nucleosides metabolism )74
ATP + dCMP = ADP + dCDP ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Pyrimidine synthesis and deprivation pathway (COVID-19 Disease Maps)1329
Biochemical pathways: part I0466
Pyrimidine metabolism038

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (46.67)18.7374
1990's3 (20.00)18.2507
2000's3 (20.00)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.56 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]